Press Releases Pharma Mar, S.A.

Equities

PHM

ES0169501022

Market Closed - BME Other stock markets 11:35:12 2024-05-08 EDT			5-day change	1st Jan Change
31.78 ^EUR	+0.70%		+4.40%	-22.64%

04-23	Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-29	Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers	01-30	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	12-05	AQ
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone	11-07	AQ
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023	23-10-19	AQ
PharmaMar increased investment in R&D in oncology by 23% in 2022	23-09-25	AQ
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa	23-09-13	AQ
PharmaMar will present new data on lurbinectedin at the IASLC 2023 World Lung Cancer Congress	23-09-11	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Oman	23-07-20	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	23-07-12	AQ
PharmaMar and Luye Pharma announce the acceptance of the registration application for the approval of lurbinectedin in China	23-06-07	AQ
PharmaMar announces abstracts to be presented at ASCO 2023	23-05-29	AQ
European Commission grants orphan drug designation to PharmaMar's lurbinectedin for the treatment of soft tissue sarcoma	23-05-15	AQ
PharmaMar starts the Nereida clinical trial with plitidepsin for the treatment of immunosuppressed patients with COVID-19	23-04-21	AQ
PharmaMar announces the approval of Zepzelca for the treatment of metastatic small cell lung cancer in Switzerland	23-03-09	AQ
PharmaMar closes the recruitment of the phase III Neptuno study with plitidepsin for the treatment of COVID-19	23-02-17	AQ
PharmaMar maintains that there was a conflict of interest in the case of Aplidin	23-02-07	AQ
PharmaMar announces the approval of Zepzelca (lurbinectedin) for the treatment of metastatic small cell lung cancer in Israel	23-02-01	AQ
PharmaMar receives orphan drug designation for lurbinectedin from the Swiss Agency for Therapeutic Products for malignant mesothelioma	22-12-28	AQ
PharmaMar leads the ONCOLIBERYX consortium together with four research centers for the development of new strategies for the administration of oncological drugs of marine origin	22-12-05	AQ
PharmaMar - The PROFARMA program grants PharmaMar an 'Excellent' company rating	22-10-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pharma Mar, S.A.

Equities

PHM

ES0169501022

Press Releases

Filters